IQVBy Calypso Research7 min read

IQVIA Holdings (IQV) Q4 2025 Earnings Analysis

A Dose of Reality as IQVIA Drops 10.7% Despite $4.4B Surge

Key Takeaways

IQVIA Holdings (IQV) reported Q4 2025 earnings with revenue of $4.4B, representing a +10.3% year-over-year change. The stock moved -10.7% on earnings day.

The bull case: Proprietary healthcare data, embedded AI-enabled workflows, and recovering R&DS demand with solid backlog and disciplined M&A into payer analytics position IQVIA for sustained mid-single to high-single digit growth with stable to improving margins.

The bear case: Rapid advances in AI, increased pharma procurement pressure, and potential erosion of R&DS book-to-bill and margins—despite acquisitions like Cedar Gate—could compress growth, limit margin expansion, and challenge the durability of IQVIA’s data and services moat over the next several years.

Financial Highlights

  • Revenue: $4.4B (+10.3% YoY)
  • Gross Profit: $292M (6.7% margin, -28.1% YoY)
  • Operating Income: $732M (16.8% margin, +1.0% YoY)
  • Net Income: $514M
  • TTM Revenue: $16.3B

Stock Performance

  • Earnings Day Move: -10.7%
  • Year-to-Date: -28.0%
  • 1-Year Return: -16.7%
  • vs. S&P 500 (since earnings): -15.0%
  • vs. Nasdaq (since earnings): -11.9%

View live IQV data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from IQVIA Holdings's Q4 2025 earnings call:

Will AI Disrupt or Enhance IQVIA’s Core Data & CRO Businesses?

Sentiment: Mixed

"Overall, I would say AI identification is a positive for our business across both clinical and commercial... our proprietary data assets, which are not stopable by horizontal AI models are more valuable than ever actually." — Ari Bousbib
"IQVIA has the largest proprietary health care information assets in the world... that access is not available... we have that access to nonpublic granular high-frequency data that nobody can license at that level of debt, which is the level of debt as required to build the agents I don't know how much to say it." — Ari Bousbib

AI’s Impact on R&DS Demand, Trial Volumes, and FSP Seats

Sentiment: Mixed

"AI delivers the most value when it's embedded in existing workflows... Most of what AI does by the way, it covers 80% of what needs to be done. But you still not need to have someone with the subject matter expertise to complete the remaining 20%." — Ari Bousbib
"We do not see any change in demand dynamics. We only see opportunities for productivity improvements. We are on it. We help our clients with those proponents. It helps us as well... our business is stable and growing and nothing has changed." — Ari Bousbib

R&DS Demand Environment, Book‑to‑Bill Sustainability, and Cancellations

Sentiment: Positive

"On the clinical side, net bookings totaled over $2.7 billion... This resulted in a net book-to-bill ratio of 1.18, reflecting the continued improvement in customer trends... I should point out that in the fourth quarter, our cancelations, while in the normal range were really slightly above the normal range due to specific esosycratic aspects of certain trials that had to be canceled." — Ari Bousbib
"Look, despite the naysayers who were telling as to Urbat we were done in any business, we booked again $10 billion of business this year... So what the book-to-bill will be next quarter, the quarter after next year, we don't project that. So I don't know. But again, demand indicators are strong. And for strong EMP demand has come back largely because funding has come back." — Ari Bousbib

Margin Outlook, Pass‑Through Dynamics, and Sharing Productivity with Clients

Sentiment: Mixed

"Now as we go into next year, you saw we're guiding towards flat. Overall, EBITDA margins and the pass-through growth will moderate going into next year into 2026." — Ronald Bruehlman
"Look, on long-term, you share productivity gains with the clients. That's no question. No secret. But you're asking about the short-term, not that it is in that sense... we offset some of this with the productivity gains when you have or with a lot of passes, then there's just that much you can do." — Ari Bousbib

Strategic Rationale and Financial Profile of the Cedar Gate Acquisition

Sentiment: Mixed

"Cedar Gate itself was a great opportunity... it transforms happier data into insights for improved patient outcomes and provide analytics to payers. It does have a great technology platform as well... in '24 it was about $125 million in revenue, and it has somewhere $33 million of adjusted EBITDA." — Ari Bousbib
"So in the U.S., we've looked at several assets before, but nothing that would be that was a sufficient scale. And obviously, the valuations were not rational at the time. Cedar Gate... has the right scale... It has to expand our solutions -- and that has some synergies with our data analytics and technologies." — Ari Bousbib

Bull Case

Proprietary healthcare data, embedded AI-enabled workflows, and recovering R&DS demand with solid backlog and disciplined M&A into payer analytics position IQVIA for sustained mid-single to high-single digit growth with stable to improving margins.

Bear Case

Rapid advances in AI, increased pharma procurement pressure, and potential erosion of R&DS book-to-bill and margins—despite acquisitions like Cedar Gate—could compress growth, limit margin expansion, and challenge the durability of IQVIA’s data and services moat over the next several years.

Looking Ahead

With revenue growing +10.3% year-over-year, the key question is whether IQVIA Holdings can sustain this growth trajectory, particularly around will AI Disrupt or Enhance IQVIA’s Core Data & CRO Businesses?. With operating margins at 16.8%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was IQVIA Holdings's revenue in Q4 2025?

IQVIA Holdings reported Q4 2025 revenue of $4.4B, representing a +10.3% year-over-year change.

Did IQVIA Holdings beat earnings expectations in Q4 2025?

The stock declined -10.7% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Proprietary healthcare data, embedded AI-enabled workflows, and recovering R&DS demand with solid backlog and disciplined M&A into payer analytics position IQVIA for sustained mid-single to high-single digit growth with stable to improving margins.

What is the bull case for IQV stock?

The bull case for IQV centers on: Proprietary healthcare data, embedded AI-enabled workflows, and recovering R&DS demand with solid backlog and disciplined M&A into payer analytics position IQVIA for sustained mid-single to high-single digit growth with stable to improving margins.

What is the bear case for IQV stock?

The bear case for IQV centers on: Rapid advances in AI, increased pharma procurement pressure, and potential erosion of R&DS book-to-bill and margins—despite acquisitions like Cedar Gate—could compress growth, limit margin expansion, and challenge the durability of IQVIA’s data and services moat over the next several years.

How has IQV stock performed since its Q4 2025 earnings?

IQV moved -10.7% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +15.0% since earnings. Year-to-date, the stock has returned -28.0%.

Browse all 400+ earnings reports →

Learn More

Analyze IQV in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for IQVIA Holdings and 400+ other stocks, explore the full platform.

Open IQV on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.